VolitionRX VNRX 深 滬
已收盤 11-06 16:00:00 美东时间
0.1959
+0.007
+3.65%
華盛通- 最 高0.20
- 今 開0.1902
- 成交量 46.81万股
- 最 低 0.1885
- 昨 收 0.189
- 總市值 588.89万
- 52周最高 7.726
- 市盈率 靜 --
- 換手率 1.56%
- 52周最低 0.1564
- 委 比 0.00%
- 總股本 3006.07万
- 歷史最高 185.60
- 量 比 0.57
- 振 幅 6.08%
- 歷史最低 0.1564
- 每 手 1
- 風險率 2.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
Reduces outstanding principal to only $0.7 million on the $2.4 million note and brings total debt reduction across both notes to over $5.0 million since June 30, 2026. Secures agreement paus...
10-27 20:17
VolitionRx Uses Private Equity Issuance to Reduce Debt
VolitionRX ( ($VNRX) ) has provided an announcement. VolitionRx Limited reporte...
09-26 06:57
VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) (NYSE:VNRX, NYSE:VNRX) (together with ...
09-17 20:19
VolitionRx Participates in Launch of DETECSEPS Program in France
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis HENDERS...
09-17 20:17
VolitionRx prepays $7.5M senior secured convertible note in full
VolitionRx (VNRX) said on Monday it prepaid in full the outstanding balance of its $7.5M senior secured convertible promissory note issued to Lind Global Asset Management. Following the prepayment, al...
09-14 20:58
VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lin...
09-14 20:20
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations. The multi-national epigenetics firm demonstrated strong momen...
08-27 19:35
Pre-Bell Movers | OKTA Appreciates by 19.2%; Here Are 20 Stocks Moving Premarket (Aug 27)
U.S. stock futures rose, led by Nvidia (+4.7%) on strong Q2 revenue and guidance. Salesforce (+13%) and Okta (+19.2%) also gained, while HP fell 7.5%. Investors await BBY, WDAY, AFRM, GAP earnings and Jackson Hole symposium signals.
08-27 16:51
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
Published in Critical Care Medicine, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HEND...
08-26 20:17
VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.57) by 49.12 percent. This is a 1316.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $398.657 thousand...
08-14 04:42
